Trials / Completed
CompletedNCT02146625
Safety, Tolerability, PK, PD, ADA of Escalating Single Dose of CJ-40002 in Healthy Male Subjects
A Dose-block Randomized, Single-blind, Placebo-controlled, Single-dosing, Dose-escalation Phase I Clinical Trial to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CJ-40002 After Subcutaneous Injection in Healthy Adult Male Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- HK inno.N Corporation · Industry
- Sex
- Male
- Age
- 19 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The objectives of this study are: * To evaluate the safety and tolerability of CJ-40002 after single SC injection in healthy male volunteers. * To evaluate the PK of CJ-40002 after single SC injection in healthy male volunteers. * To evaluate the PD of CJ-40002 after single SC injection in healthy male volunteers. * To evaluate the ADA of CJ-40002 after single SC injection in healthy male volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CJ-40002 |
Timeline
- Start date
- 2014-11-01
- Primary completion
- 2015-03-01
- Completion
- 2015-09-01
- First posted
- 2014-05-26
- Last updated
- 2016-12-29
Source: ClinicalTrials.gov record NCT02146625. Inclusion in this directory is not an endorsement.